Can you prepare slides on targeted therapies for paraproteinemia?

Targeted Therapies for Paraproteinemia

Overview of Treatment Approach

The targeted therapy approach for paraproteinemia depends critically on the underlying hematologic disorder, with multiple myeloma representing the most common and best-studied condition requiring aggressive treatment. The therapeutic landscape has evolved dramatically with novel agents including proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, antibody-drug conjugates, and cellular therapies 1.

First-Line Therapy Selection

Transplant-Eligible Patients

• Induction regimens should include:
  • Daratumumab-based combinations (DaraVd or DaraVRd) as preferred options
  • Alternative approved regimens: KRd, IxaRd, EloRd, SelVd, or Kd 1

Transplant-Ineligible Patients

• Similar combination approaches apply
• Treatment intensity adjusted based on frailty status and comorbidities

Second-Line Therapy Algorithm

For Lenalidomide-Refractory Disease (First Relapse)

The optimal approach prioritizes anti-CD38 antibody combinations with carfilzomib or belantamab-based regimens 1:

• First-tier options:

  • DaraKd (daratumumab-carfilzomib-dexamethasone)
  • IsaKd (isatuximab-carfilzomib-dexamethasone)
  • BelaPd (belantamab mafodotin-pomalidomide-dexamethasone)
  • BelaVd (belantamab mafodotin-bortezomib-dexamethasone)

• Alternative options if above unavailable:

  • DaraPd, SelVd, PVd, or DaraVd 1

For Lenalidomide and Bortezomib Double-Refractory Disease

CAR T-cell therapy (cilta-cel) should be prioritized in eligible patients who have not received or remain sensitive to anti-CD38 antibodies 1. If CAR T unavailable:

• BelaPd
• DaraKd or IsaKd
• DaraPd

For Triple-Class Refractory Disease (Lenalidomide + Bortezomib + Anti-CD38)

Cilta-cel and BelaPd are the only regimens with proven efficacy in this population and should be prioritized 1. These are the only agents tested specifically in patients previously exposed to both lenalidomide and daratumumab in early relapse.

Third-Line and Beyond

Pomalidomide-Based Combinations

DaraPd (daratumumab-pomalidomide-dexamethasone) demonstrated superior outcomes in the APOLLO trial 1:

• Median PFS: 12.4 months vs 6.9 months (HR 0.63, P=0.002)
• Median OS: 34.4 months vs 23.7 months (HR 0.82, P=0.2)

Heavily Pre-Treated Patients

For patients with ≥3 prior lines 2:

• Selinexor-dexamethasone (Sd): mPFS 3.7 months, mOS 8.6 months
• Belantamab mafodotin monotherapy: mPFS 2.9-4.9 months depending on dose
  • Critical caveat: High rate of keratopathy (21-27% grade 3-4) requiring ophthalmologic monitoring

Special Populations and Considerations

Patients with t(11;14) Translocation

• VenVd (venetoclax-bortezomib-dexamethasone) is specifically indicated for lenalidomide-refractory, PI-sensitive patients with this cytogenetic abnormality 2

Re-Treatment with Anti-CD38 Antibodies

Retreatment with anti-CD38 antibodies immediately after refractoriness yields poor results (median PFS <6 months) 1. Evidence suggests:

• Treatment-free interval of ≥1 year may restore some sensitivity
• Cells from patients with >1 year off daratumumab show greater sensitivity than those with <1 year exposure
• This approach requires clinical validation but represents the only rational retreatment strategy

Proteasome Inhibitor Selection with Daratumumab

Carfilzomib combined with daratumumab (DaraKd) provides superior outcomes compared to bortezomib or ixazomib combinations 1.

Emerging Immunotherapies

CAR T-Cell Therapy

• bb2121 (idecabtagene vicleucel) showed 85% objective response rate with 45% complete responses in multi-refractory disease 2
• Median PFS: 11.8 months
• Major toxicities: Cytokine release syndrome (76%), neurological effects (42%)

Bispecific T-Cell Engagers

• Multiple BCMA-targeted agents under investigation
• Similar efficacy signals to CAR T-cells in early studies 2

Non-Myeloma Paraproteinemic Conditions

POEMS Syndrome and AL Amyloidosis

Treatment targets the underlying plasma cell disorder 3:

• Melphalan, thalidomide, lenalidomide, bortezomib
• Daratumumab for AL amyloidosis
• Autologous stem cell transplant for eligible patients 4

Anti-MAG Neuropathy

• Rituximab may reduce autoantibody levels but shows variable efficacy 3, 5
• Conventional CIDP treatments (steroids, IVIG, plasmapheresis) offer minimal benefit 3

Monoclonal Gammopathy of Cutaneous Significance (MGCS)

Co-management with hematology and treatment addressing the underlying immunoglobulin disorder is warranted for serious cutaneous manifestations 6.

Critical Pitfalls to Avoid

1. Do not use conventional CIDP therapies for paraproteinemic neuropathies—they are ineffective 3
2. Avoid immediate anti-CD38 retreatment in refractory patients without adequate treatment-free interval 1
3. Monitor for keratopathy with belantamab mafodotin—requires ophthalmologic surveillance 2
4. Screen for t(11;14) to identify venetoclax-eligible patients 2
5. Assess CAR T eligibility early in lenalidomide-refractory patients before triple-class exposure 1